فليبانسرين
|
فليبانسرين Flibanserin
| |
| الاسم النظامي (أيوپاك) | |
| الاسم النظامي (أيوپاك) | |
| 1-[2-[4-(3-trifluoromethyl phenyl) piperazin-1-yl] ethyl] benzimidazol- [1H]-2-one | |
| المعينات Identifiers | |
| رقم CAS | |
| كود ATC | none |
| PubChem | |
| بيانات كيميائية | |
| الصيغة | 202134 |
| كتلة جزيئية | 390.40 g/mol |
| بيانات الحركية الدوائية Pharmacokinetic | |
| التوافر الحيوي | ? |
| الأيض | ? |
| عمر النصف | ? |
| اخراج | ? |
| اعتبارات علاجية | |
| فئة السلامة أثناء الحمل |
? |
| الوضع القانوني | |
| المسارات | ? |
فليبانسرين Flibanserin (BIMT-17) هوعقار تنتجه بورنگر إنگلهايم Boehringer Ingelheim. It is currently being investigated as a drug for women with decreased sexual desire. It is a serotonin receptor agonist, a serotonin receptor antagonist, and a dopamine D4 receptor partial agonist that had initially been developed as an anti-depressant. As with Viagra, the purported aphrodisiac effects of flibanserin were discovered serendipitously after it was trialled as an antidepressant and patients were reluctant to return the unused medication at the end of the trial.
On November 16, 2009, Boehringer Ingelheim reported that late-stage trials showed that the drug promoted sexual desire and increased the number of "satisfying sexual events" in women suffering from abnormally low libido.
The results of four Phase III studies involving more than 2,000 pre-menopausal woman suffering from so-called Hypoactive Sexual Desire Disorder (HSDD) were presented at the congress of the European Society for Sexual Medicine in Lyon, France.
Unlike Procter & Gamble's hormone patch Intrinsa, targeted at woman after the menopause, flibanserin directly manipulates the chain of chemical reactions in the brain believed to trigger sexual desire.
نطقب:Pharm-stub
انظر أيضاً
- ABT-670
- ABT-724
- Bremelanotide
- Cabergoline
- Intrinsa
- Melanotan II
- PF-219,061
- Pramipexole
- Tibolone
الهامش
-
^ Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S (2002). "Pharmacology of flibanserin". CNS Drug Rev. 8 (2): 117–142. Unknown parameter
|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ Jolly E, Clayton A, Thorp J, Lewis-D’Agostino D, Wunderlich G, Lesko L. Design of Phase III pivotal trials of flibanserin in female Hypoactive Sexual Desire Disorder (HSDD). Sexologies. Volume 17, Supplement 1, April 2008, Pages S133-S134. DOI:10.1016/S1158-1360(08)72886-X
-
^ D'Aquila P, Monleon S, Borsini F, Brain P, Willner P (1997). "Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant". European Journal of Pharmacology. 340 (2–3): 121–32. PMID 9537806. Unknown parameter
|month=ignored (help)CS1 maint: multiple names: authors list (link) -
^ Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R (2003). "Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors". Br J Pharmacol. 139 (7): 1281–8. doi:10.1038/sj.bjp.0705341. Unknown parameter
|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ "Boehringer Drug Shown to Kindle Female Sex Drive". ABC News. November 16, 2009. Retrieved November 16, 2009.
وصلات خارجية
- Viagra for women?.
- Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain
- Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety
- Effect of flibanserin (BIMT 17), fluoxetine, 8-OH-DPAT and buspirone on serotonin synthesis in rat brain
